Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis (Q37054331)

18 August 2017

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis (English)

1 reference

cost-effectiveness analysis

18 August 2017

1 reference

1 reference

1 reference

5

Yair Lotan

1 reference

18 August 2017

3

Claus G Roehrborn

1 reference

18 August 2017

4

Scott M Lippman

1 reference

18 August 2017

Robert S Svatek

1

1 reference

18 August 2017

J Jack Lee

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

112

1 reference

18 August 2017

5

1 reference

18 August 2017

1058-1065

1 reference

The influence of finasteride on the development of prostate cancer

18 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

The cost of prostate cancer chemoprevention: a decision analysis model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Utilities for prostate cancer health states in men aged 60 and older.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Benefits, risks and costs of immunization for measles, mumps and rubella

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Patient and Community Preferences for Outcomes in Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Utility scores for chronic conditions in a community-dwelling population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

The prostate cancer prevention trial: design, biases and interpretation of study results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

What is the price of life and why doesn't it increase at the rate of inflation?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Adenocarcinoma of the prostate: an expensive way to die.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Screening for prostate cancer. A decision analytic view

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

A quantitative analysis of the costs and benefits of prostate cancer screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23276

7 January 2021

Identifiers

DOI

10.1002/CNCR.23276

1 reference

release_7slmya35ifd4bbacull7slmpi4

18 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7slmya35ifd4bbacull7slmpi4

24 November 2022

mapped directly with Wikidata item

1 reference